Keir, A.Rumbold, A.Shepherd, E.Mcintyre, S.Groves, C.Cavallaro, A.Crowther, C.Callander, E.2021-12-202021-12-202022Australian and New Zealand Journal of Obstetrics and Gynaecology, 2022; 62(1):168-1710004-86661479-828Xhttps://hdl.handle.net/2440/133826First published: 29 November 2021Previous work demonstrated that implementing a quality improvement (QI) program improves the uptake of guideline-recommended antenatal magnesium sulphate, a critical intervention known to reduce cerebral palsy risk. Here we estimate potential cost savings attributable to the improved uptake. By expanding coverage from 63 to 83% of eligible women, we estimated that five children potentially would not have received a diagnosis of cerebral palsy, a potential cost saving of $AU4.8 million in lifetime healthcare costs. Our findings strengthen the case for embedding QI approaches in perinatal care to reduce the incidence of cerebral palsy.en© 2021 The Royal Australian and New Zealand College of Obstetricians and Gynaecologistsmagnesium sulphatecerebral palsyquality improvementcost-benefit analysisJournal article10.1111/ajo.134592021-12-20595454Keir, A. [0000-0003-1692-5676]Rumbold, A. [0000-0002-4453-9425]Shepherd, E. [0000-0002-9669-788X]Crowther, C. [0000-0002-9079-4451]